Modafinil, Sleep Architecture and Cocaine Relapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01137396
Recruitment Status : Completed
First Posted : June 4, 2010
Results First Posted : April 27, 2016
Last Update Posted : April 27, 2016
Information provided by (Responsible Party):
Yale University

June 3, 2010
June 4, 2010
March 24, 2016
April 27, 2016
April 27, 2016
April 2010
February 2015   (Final data collection date for primary outcome measure)
%Cocaine Free Urines [ Time Frame: 3x/week ]
Number of cocaine-free urines [ Time Frame: 3x/week ]
Complete list of historical versions of study NCT01137396 on Archive Site
Change in N3 (Slow-wave) Sleep Time [ Time Frame: change from week 1 to week 2 of inpatient treatment ]
Polysomnographically measured sleep [ Time Frame: 5 times over 8 weeks ]
Not Provided
Not Provided
Modafinil, Sleep Architecture and Cocaine Relapse
Modafinil, Sleep Architecture and Cocaine Relapse
The medication modafinil has been shown to reduce cocaine use in some cocaine users. The investigators have shown that modafinil taken in the morning improves sleep in chronic cocaine users. The investigators hypothesize that the beneficial effects of modafinil in reducing cocaine use may be related to specific effects modafinil has on sleep. This study will measure sleep and cocaine use in cocaine dependent persons who are trying to stop using cocaine, and will test the connection between modafinil's effects on sleep and cocaine use.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Cocaine Dependence
  • Drug: Modafinil
    Modafinil 400mg PO QDaily following up-titration for ~8weeks
  • Behavioral: Cognitive Behavioral Therapy
    Once weekly cognitive behavioral therapy for cocaine dependence
  • Experimental: Modafinil
    • Drug: Modafinil
    • Behavioral: Cognitive Behavioral Therapy
  • Placebo Comparator: Placebo
    Intervention: Behavioral: Cognitive Behavioral Therapy
Angarita GA, Canavan SV, Forselius E, Bessette A, Pittman B, Morgan PT. Abstinence-related changes in sleep during treatment for cocaine dependence. Drug Alcohol Depend. 2014 Jan 1;134:343-347. doi: 10.1016/j.drugalcdep.2013.11.007. Epub 2013 Nov 17.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2015
February 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 25-50 years of age;
  • voluntary, written, informed consent;
  • seeking but not currently enrolled in treatment for cocaine use;
  • self-reported, current use of cocaine by smoked or intravenous route at least one time each week in the past month, with ≥1g used within a single 24-hour period and ≥3g used in the month;
  • positive urine test for cocaine (benzoylecognine) at the time of screening and study start
  • dependence on cocaine in the past year as measured by a score ≥ 3 on the Severity of Dependence Scale(Kaye and Darke, 2002);
  • chronic use in the past year as determined by self-reported use in at least 9 of the past 12 months;
  • lifetime diagnosis of cocaine dependence with a duration of at least 2 years as determined by the Structured Clinical Interview for DSM-IV (SCID).

Exclusion Criteria:

  • evidence of any neurological condition or a chronic medical condition including diabetes, cardiovascular disease or history of cardiac problems, HIV-seropositivity, liver disease, hypertension, asthma requiring daily medication, dementia, movement disorder, history of head trauma with loss of consciousness, sleep apnea, narcolepsy, restless leg syndrome, periodic limb movement disorder, REM sleep disorder, pharmacological treatment for insomnia of any type within the past 6 months, glaucoma, severe respiratory insufficiency, seizure disorder, or if in the past three months they have taken any medications that affect sleep, or are currently taking any regularly dosed prescription medication or any prn medication that is used on average more than 1x/week
  • evidence of chronic sleep disorder including sleep apnea, narcolepsy, periodic limb movement disorder, restless leg syndrome as determined by medical history, Sleep Disorders Questionnaire(Douglass, 1994), or by polysomnography (following enrollment)
  • current dependence on any drugs other than cocaine or nicotine or lifetime dependence on alcohol, benzodiazepines, or opiates, or any non-substance related Axis I disorder as determined by SCID
  • current use of alcohol in excess of 3x/week AND 21 standard drinks/week in the past month or non-zero breathalyzer at screening or study start
  • current use of cannabis in the past month
  • positive urine toxicology test for opiates, methadone, amphetamines, barbiturates, benzodiazepines, PCP, methaquolone, and propoxyphene at the time of screening or positive test for any of those listed plus cannabis at the time of study start
  • pregnancy as determined by serum β-HCG at screening or lactating per report
  • females: unwillingness to use barrier contraceptives during sexual intercourse for the duration of the study
  • known hypersensitivity to modafinil.
Sexes Eligible for Study: All
25 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Yale University
Yale University
Not Provided
Principal Investigator: Peter Morgan, MD, PhD Yale University
Yale University
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP